The University of Southampton
University of Southampton Institutional Repository

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults
Streptococcus pneumoniae-related infections are a major cause of morbidity and mortality in people of all ages worldwide. Pneumococcal vaccine development started in 1911 with a whole cell vaccine and more recently multivalent plain polysaccharide and polysaccharide conjugate vaccines have been developed. The recent vaccines rely on capsular polysaccharide antigens to induce serotype-specific immune responses. We summarize here the presentations on pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) given during the integrated symposium organized and funded by Pfizer International Operations during the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 31 March to 3 April 2012, London, UK. A dramatic reduction in the incidence of invasive pneumococcal diseases (IPD) due to vaccine serotypes (VST-IPD) has been reported since the introduction of a hepta-valent pneumococcal conjugate vaccine (PCV7). An indirect (herd) effect has been demonstrated to be associated with PCV7 infant vaccination programmes, with many studies reporting reductions in VST-IPD in populations that are not eligible for PCV7 vaccination. Since 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) has been introduced into national immunization programmes and results from early surveillance suggest that this vaccine also has an impact on the serotypes unique to PCV13, as well as continuing to protect against the PCV7 serotypes. Data from a passive surveillance system in Europe in 2009, for instance, showed that the highest incidence of IPD remains in those aged >65 years and in children <5 years. PCV13 has now been licensed for vaccination of adults >50 years based on safety and immunogenicity data; an efficacy trial is being conducted. Regardless of previous pneumococcal vaccination status, if the use of 23-valent polysaccharide is considered appropriate, it is recommended to give PCV13 first. Novel immunization strategies remain the only practical means to reduce significantly the remaining global mortality and morbidity due to S. pneumoniae in adults
adult vaccination, burden of disease, community-acquired pneumonia, invasive pneumococcal disease, pneumococcal conjugate vaccines, pneumococcal disease, vaccine
1198-743X
1-9
Durando, P.
ac458299-2747-402b-b27a-8fb1ce0dd241
Faust, S.N.
f97df780-9f9b-418e-b349-7adf63e150c1
Fletcher, M.
114df9b1-af0d-48dd-8871-2173afe8a539
Krizova, P.
6c0f620d-fa46-4e7e-ab5b-fcdac8610987
Torres, A.
6f6cb97f-8162-440c-a426-b96f19ebd4a1
Welte, T.
f59521f9-fc45-4b08-9fb2-5d3e711f4696
Durando, P.
ac458299-2747-402b-b27a-8fb1ce0dd241
Faust, S.N.
f97df780-9f9b-418e-b349-7adf63e150c1
Fletcher, M.
114df9b1-af0d-48dd-8871-2173afe8a539
Krizova, P.
6c0f620d-fa46-4e7e-ab5b-fcdac8610987
Torres, A.
6f6cb97f-8162-440c-a426-b96f19ebd4a1
Welte, T.
f59521f9-fc45-4b08-9fb2-5d3e711f4696

Durando, P., Faust, S.N., Fletcher, M., Krizova, P., Torres, A. and Welte, T. (2013) Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. [in special issue: Pneumococcal Conjugate Vaccines] Clinical Microbiology and Infection, 19, supplement 1, 1-9. (doi:10.1111/1469-0691.12320). (PMID:24083785)

Record type: Article

Abstract

Streptococcus pneumoniae-related infections are a major cause of morbidity and mortality in people of all ages worldwide. Pneumococcal vaccine development started in 1911 with a whole cell vaccine and more recently multivalent plain polysaccharide and polysaccharide conjugate vaccines have been developed. The recent vaccines rely on capsular polysaccharide antigens to induce serotype-specific immune responses. We summarize here the presentations on pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) given during the integrated symposium organized and funded by Pfizer International Operations during the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 31 March to 3 April 2012, London, UK. A dramatic reduction in the incidence of invasive pneumococcal diseases (IPD) due to vaccine serotypes (VST-IPD) has been reported since the introduction of a hepta-valent pneumococcal conjugate vaccine (PCV7). An indirect (herd) effect has been demonstrated to be associated with PCV7 infant vaccination programmes, with many studies reporting reductions in VST-IPD in populations that are not eligible for PCV7 vaccination. Since 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) has been introduced into national immunization programmes and results from early surveillance suggest that this vaccine also has an impact on the serotypes unique to PCV13, as well as continuing to protect against the PCV7 serotypes. Data from a passive surveillance system in Europe in 2009, for instance, showed that the highest incidence of IPD remains in those aged >65 years and in children <5 years. PCV13 has now been licensed for vaccination of adults >50 years based on safety and immunogenicity data; an efficacy trial is being conducted. Regardless of previous pneumococcal vaccination status, if the use of 23-valent polysaccharide is considered appropriate, it is recommended to give PCV13 first. Novel immunization strategies remain the only practical means to reduce significantly the remaining global mortality and morbidity due to S. pneumoniae in adults

Full text not available from this repository.

More information

Published date: October 2013
Keywords: adult vaccination, burden of disease, community-acquired pneumonia, invasive pneumococcal disease, pneumococcal conjugate vaccines, pneumococcal disease, vaccine
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 360083
URI: http://eprints.soton.ac.uk/id/eprint/360083
ISSN: 1198-743X
PURE UUID: 379cc36c-bfd4-4c46-8ba0-f9cf8312c15e
ORCID for S.N. Faust: ORCID iD orcid.org/0000-0003-3410-7642

Catalogue record

Date deposited: 25 Nov 2013 13:44
Last modified: 18 Feb 2021 17:07

Export record

Altmetrics

Contributors

Author: P. Durando
Author: S.N. Faust ORCID iD
Author: M. Fletcher
Author: P. Krizova
Author: A. Torres
Author: T. Welte

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×